Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 5/20 | 0.46 |
| ▸ | GSK3A | P49840 | 4/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16137332 | 0.84 | LRRK2 (0.47) | AURKACDK2MAPK1ITKSYK | |
| SCHEMBL16134078 | 0.83 | SYK (0.44) | AURKAMAPKAPK2SYKLRRK2MAPK3 | |
| SCHEMBL5413325 | 0.78 | LRRK2 (0.62) | PLK1PTK2BMEN1CYP1A2CYP3A4 | |
| SCHEMBL5416315 | 0.77 | IGF1R (0.52) | PLK1PTK2BMEN1CYP1A2CYP3A4 | |
| SCHEMBL5408522 | 0.77 | LRRK2 (0.65) | PLK1PTK2BMEN1MAPTKMT2A | |
| SCHEMBL5418647 | 0.77 | IGF1R (0.59) | PLK1PTK2BMEN1CYP1A2CYP3A4 | |
| SCHEMBL24690431 | 0.77 | FGFR4 (0.51) | PTK2SYKLRRK2MAPK3 | |
| SCHEMBL5413522 | 0.76 | PTK2 (0.54) | PLK1PTK2BMEN1CYP1A2CYP3A4 | |
| SCHEMBL5415257 | 0.76 | MEN1 (0.50) | PLK1PTK2BMEN1CYP1A2CYP3A4 | |
| SCHEMBL5413297 | 0.75 | GSK3B (0.53) | PLK1PTK2BMEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189794-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-01-29 | — | — | US | disclosed |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-01-25 | — | — | US | disclosed |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-01-25 | — | — | US | disclosed |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
| US-9695132-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2017-07-04 | — | — | US | disclosed |
| US-9663524-B2 | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors | CELGENE CAR LLC (BM) | 2017-05-30 | — | — | US | disclosed |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-08-04 | — | — | US | disclosed |
| US-9321786-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-18 | — | — | US | disclosed |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PLK1 1251/4885PTK2B 2507/4885MEN1 606/4885 |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | PLK1 23/4885PTK2B 178/4885MEN1 3268/4885 |
| US-10189794-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | PLK1 1251/4885PTK2B 2507/4885MEN1 606/4885 |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PLK1 1251/4885PTK2B 2507/4885MEN1 606/4885 |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PLK1 1251/4885PTK2B 2507/4885MEN1 606/4885 |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | PLK1 23/4885PTK2B 178/4885MEN1 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.